Immix Biopharma Stock Forecast

Stock Price Forecast

According to 5 analysts polled by S&P Global, Immix Biopharma stock has a consensus rating of "Buy" and an average price target of $17.56. The average 1-year stock price forecast is 96.42% higher than the current stock price, while the lowest is $14.8 (+65.55%) and the highest is $23 (+157.27%).

Price Target: $17.56 (+96.42%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$14.8	$17.56	$15	$23
Change	+65.55%	+96.42%	+67.79%	+157.27%

* Price targets were last updated on Mar 30, 2026.

Analyst Ratings

The average analyst rating for Immix Biopharma stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Dec '25	Jan '26	Feb '26	Mar '26	Apr '26	May '26
Strong Buy	1	1	1	1	1	1
Buy	0	0	1	4	4	4
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	1	1	2	5	5	5

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Robert Burns HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Reiterates $15	Strong Buy	Reiterates	$15	+67.79%	Mar 30, 2026
Graig Suvannavejh Mizuho	Mizuho	Buy Maintains $14 → $15	Buy	Maintains	$14 → $15	+67.79%	Mar 30, 2026
Reni J. Benjamin Citizens	Citizens	Buy Reiterates $23	Buy	Reiterates	$23	+157.27%	Mar 27, 2026
Robert Burns HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Maintains $12 → $15	Strong Buy	Maintains	$12 → $15	+67.79%	Mar 27, 2026
Judah Frommer Morgan Stanley	Morgan Stanley	Buy Initiates $20	Buy	Initiates	$20	+123.71%	Mar 25, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

n/a

Revenue Next Year

63.63M

EPS This Year

-0.85

from -0.89

EPS Next Year

-0.97

from -0.85

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	-	-	-	-	-	-	63.63M
Revenue Growth	-	-	-	-	-	-	-
EPS	-6.64	-0.59	-0.89	-0.76	-0.89	-0.85	-0.97
EPS Growth	-	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-	-
No. Analysts	-	-	-	-	-	7	6

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2026	2027
High	n/a	98.6M
Avg	n/a	63.6M
Low	n/a	17.3M

Revenue Growth

Revenue Growth	2026	2027
High	-	-
Avg	-	-
Low	-	-

EPS Forecast

EPS	2026	2027
High	-0.78	-0.66
Avg	-0.85	-0.97
Low	-0.94	-1.45

EPS Growth

EPS Growth	2026	2027
High	-	-
Avg	-	-
Low	-	-

Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.